VolitionRx Highlights Diagnostic Licensing Talks, Cancer Detection Progress And Debt Reduction Of Over $5M
Benzinga Newsdesk 2 days ago
News
Peer-reviewed validation in sepsis, >95% early-stage cancer detection in a blinded cohort, a government-funded sepsis program in France, licensing discussions with more than a dozen diagnostic companies worldwide, an expanded Fujifilm agreement to include cats, and over $5 million of debt reduction
HENDERSON, Nev., Nov. 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, today highlights the progress it has made across its Nu.Q® platform in 2026. Volition now has wide-ranging clinical evidence, partner programs and licensing discussions in place across its key product pillars, each targeting multi-billion-dollar markets.
- Volition is in discussions with more than a dozen of the world's leading diagnostic and liquid biopsy companies to licence its proprietary platform protected by over 70 patents.
- Volition's model is to co-develop with third parties and license its technology for upfront and milestone payments, royalties and other recurring revenue, while keeping its own costs low.
